Targeted News Service

FDA Determines Regulatory Review Period for Alfapump to Assist With Patent Extension
February 06, 2026

WASHINGTON, Feb. 6 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced that it has calculated the regulatory review period for the medical device Alfapump. This determination follows an application by Sequana Medical NV to the U.S. Department of Commerce Patent and Trademark Office for a patent term extension.

Alfapump is an implanted device indicated for adult patients suffering from refractory or recurrent ascites due to liver cirrhos . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form